Based on this mouse model of prostate cancer, we confirmed that TMED3 downregulation decreased p-FOXO1a and p-FOXO3a levels rather than FOXO1a and FOXO3a levels (Fig. 6). Here, TMED3 is linked to prostate carcinoma.